Neuronal Ceroid Lipofuscinosis, Congenital
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
A model combining two cancer-related glycoproteins (THBS1 and CTSD) and %fPSA can improve PCa diagnosis and may reduce the number of unnecessary prostate biopsies because of its improved specificity for PCa when compared to %fPSA alone.
|
30216634 |
2019 |
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Conclusively, the use of CTSD and THBS1 together with commonly used parameters for PCa diagnosis such as %fPSA and age has the potential to improve the diagnosis of PCa.
|
28767721 |
2017 |
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Compared with the LNCaP/pcDNA3.1 and LNCaP cells, the expression of vimentin, cathepsin D, MMP-2 and uPAR were up-regulated in LNCaP/HIF-1alpha, whereas the expression of E-cadherin was down-regulated.
|
16956360 |
2006 |
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Although this study did not find independent prognostic status for cathepsin D in prostate cancer, the correlation with tumor grade and DNA ploidy status is noteworthy and the inter-relationship of outcome variables may prove of interest and warrant further evaluation of this potential predictor or CO-predictor of disease outcome.
|
7541934 |
1995 |
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
The ratios of cathepsin B to stefin A, cathepsin D to stefin A, cathepsin B to stefin B and cathepsin D to stefin B of the HCC group were significantly higher than that of the surrounding noncancerous group.
|
26753874 |
2016 |
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
This is the first report that serum ConA-pCD is increased significantly in HCC and is potentially useful as a serological biomarker for diagnosis of HCC.
|
24259486 |
2014 |
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
CTD_human |
Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS.
|
21472284 |
2012 |
Amyotrophic Lateral Sclerosis, Sporadic
|
0.310 |
Biomarker
|
disease |
BEFREE |
The cytoplasm of AHCs showed diffuse immunoreactivity for LC3, cathepsin B and cathepsin D in both sALS and controls.
|
31504678 |
2019 |
Degenerative polyarthritis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
Rheumatoid Arthritis
|
0.310 |
Biomarker
|
disease |
CTD_human |
From transcriptome to proteome: differentially expressed proteins identified in synovial tissue of patients suffering from rheumatoid arthritis and osteoarthritis by an initial screen with a panel of 791 antibodies.
|
12833524 |
2003 |
Amyotrophic Lateral Sclerosis, Sporadic
|
0.310 |
Biomarker
|
disease |
CTD_human |
Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis.
|
11796754 |
2002 |
Rheumatoid Arthritis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization.
|
7612047 |
1995 |
Degenerative polyarthritis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
To compare the expression of cathepsin L, cathepsin D, and collagenase messenger RNA (mRNA) in synovial specimens from patients with rheumatoid arthritis (RA) and osteoarthritis (OA).
|
7612047 |
1995 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In mice and humans CTSD dysfunction underlies the congenital variant (CLN10) of neuronal ceroid lipofuscinosis (NCL).
|
31282275 |
2020 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
Biomarker
|
disease |
BEFREE |
This functional relationship between PGRN and cathepsin D provides a possible explanation for overlapping NCL-like pathology observed in patients with mutations in PGRN or CTSD, the gene encoding cathepsin D. Together, our work identifies PGRN as an activator of lysosomal cathepsin D activity, and suggests that decreased cathepsin D activity due to loss of PGRN contributes to both FTD and NCL pathology in a dose-dependent manner.
|
29036611 |
2017 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neurologic phenotypes of cathepsin D (CTSD)-deficient mice, a murine model of neuronal ceroid lipofuscinoses, indicate the importance of CTSD for the maintenance of metabolism in central nervous system neurons.
|
28502476 |
2017 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Neuroectoderm-specific deletion of cathepsin D in mice models human inherited neuronal ceroid lipofuscinosis type 10.
|
26232697 |
2016 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
Biomarker
|
disease |
BEFREE |
CTSD is the gene encoding Cathepsin D (CTSD), a lysosomal protein hydrolase, and homozygous CTSD deficiency results in neuronal ceroid-lipofuscinosis, which is characterized by the early onset, progressive neurodegeneration.
|
26448324 |
2015 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
Biomarker
|
disease |
BEFREE |
In Grn(-/-) mice the lysosomal proteins cathepsin D (CTSD), LAMP (lysosomal-associated membrane protein) 1 and the NCL storage components saposin D and subunit c of mitochondrial ATP synthase (SCMAS) were all found to be elevated.
|
24619111 |
2014 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although functions are defined for some of the soluble proteins that are defective in NCL (cathepsin D, PPT1, and TPP1), the primary function of the other proteins defective in NCLs (CLN3, CLN5, CLN6, CLN7, and CLN8) remain poorly defined.
|
20680390 |
2011 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Deficiency in Cathepsin D (CtsD), the major cellular lysosomal aspartic proteinase, causes the congenital form of neuronal ceroid lipofuscinoses (NCLs).
|
20489146 |
2010 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To date, 10 NCL entities (CLN1-CLN10) are known and characterized by accumulation of autofluorescent storage material, age of onset and clinical symptoms.
|
19807737 |
2010 |
Neuronal Ceroid-Lipofuscinoses
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Remaining neurons, astrocytes and macrophages contained PAS-positive storage material with granular ultrastructure and immunoreactivity against sphingolipid activator protein D. A diagnosis of congenital NCL was rendered with a novel mutation, c.299C > T (p.Ser100Phe) in exon 3 of the cathepsin D gene.
|
18762956 |
2009 |